Deals in Pharmaceutical & Healthcare Industry Decreased in Q3 2015

GlobalData’s “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q3 2015” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions registered in the pharmaceutical and healthcare industry in Q3 2015. The report presents detailed comparative data on the number of deals and their value in the past five quarters subdivided into deal types, segments, and geographies. The report also offers information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database and through primary and secondary research.

M&A’s Decreased In Q3 2015

Merger and acquisition (M&A) deals, including asset purchases, recorded a decrease in the number of deals and an increase in deal values in Q3 2015 with 259 deals worth USD77.2 billion, compared to 280 deals worth USD70.7 billion in Q3 2014. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q3 2015, compared to 273 deals worth USD67.4 billion in Q2 2015.

The central nervous system therapeutics market accounted for the majority of M&As with 165 deals worth USD203.9 billion between Q3 2014 and Q3 2015. Oncology therapeutics market followed in second place with 164 deals worth USD188.5 billion.

Deal Value Of Partnerships Increased In Q3 2015

Partnerships reported an increase in the number of deals and deal values with 172 deals worth USD4.2 billion in Q3 2015, compared to 154 deals worth USD2.8 billion in Q3 2014. On a quarter-on-quarter basis, the number of partnerships and their values decreased in Q3 2015, compared to 297 deals worth USD8.5 billion in Q2 2015.

Pharmaceutical and healthcare companies entered into 103 partnerships for Preclinical stage products, which accounted for 32% of the deals from Q3 2014 to Q3 2015. Products in Marketed stage stood second with 56 deals, which accounted for 17% of the deals.

The oncology therapeutics market stood at the top in the pharmaceutical and healthcare industry with 280 partnerships worth USD14.4 billion between Q3 2014 and Q3 2015. The central nervous system therapeutics market followed with 114 deals worth USD3.4 billion in the same period.

Licensing Deals Repoted An Increase In Number In Q3 2015

Licensing agreements reported an increase in the number of deals and deal values in Q3 2015 with 143 deals worth USD11.8 billion in Q3 2015, as compared to 134 deals worth USD7.4 billion in Q3 2014. On a quarter-on-quarter basis, the number of licensing deals and their values increased in Q3 2015, compared to 139 deals worth USD6.4 billion in Q2 2015.

Licensing agreements recorded an increase in upfront payments and milestone payments in Q3 2015. A total of USD598.5m and USD8.2 billion were reported as upfront and milestone payments in Q3 2015, compared to USD286.1m and USD4.1 billion, respectively in Q3 2014. On a quarter-on-quarter basis, upfront payments and milestone payments increased in Q3 2015, compared to USD583.6m and USD2.9 billion, respectively, in Q2 2015.

In licensing by phase, products in Preclinical stage recorded 94 deals, which accounted for 23% of the total deals between Q3 2014 and Q3 2015. In second place, products in Phase II accounted for 20% of the deals.

Venture Capital Investments Increased In Q3 2015

The venture capital (VC) segment reported 150 deals worth USD2.7 billion in Q3 2015, as compared to 246 deals worth USD2.3 billion in Q3 2014. On a quarter-on-quarter basis, the number of VC deals and their values decreased in Q3 2015, compared to 178 deals worth USD3.3 billion in Q2 2015. Besides, 23 PE deals worth USD347.1m were reported in Q3 2015.

New Enterprise Associates, Inc. topped the list of venture financing firms by participating in 21 transactions worth USD771.9m in the last five quarters (Q3 2014 – Q3 2015).

Deals In North America Reported A Decrease In Q3 2015

North America recorded a decrease in the number of deals and an increase in deal values in Q3 2015. The region registered 621 deals worth USD74.9 billion in Q3 2015, compared to 715 deals worth USD62.9 billion in Q3 2014. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q3 2015, when compared to 805 deals worth USD118.9 billion in Q2 2015.

Europe recorded an increase in the number of deals and deal values in Q3 2015 with 318 deals worth USD71.3 billion, as compared to 279 deals worth USD63.8 billion in Q3 2014. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q3 2015, when compared to 394 deals worth USD30.4 billion in Q2 2015.

Asia Pacific recorded an increase in the number of deals and deal values in Q3 2015. The region reported 252 deals worth USD23.3 billion in Q3 2015, as compared to 226 deals worth USD18.6 billion in Q3 2014. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q3 2015, when compared to 284 deals worth USD22.1 billion in Q2 2015.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s